logo

For the Inventor, By the Inventor

Lexington, MA, United States of America

Dicerna Pharmaceuticals, Inc.


USPTO Granted Patents = 102

% Expired Patents = 8.8



Trademarks = 5

Forward Citations = 398

Loading Chart...
Loading Chart...

37 inventors (with patents filed for the assignee):

goldMedal Bob Dale Brown (79 out of 96 patents)

silverMedal Henryk T Dudek (57 out of 65 patents)

bronzeMedal Marc Abrams (14 out of 15 patents)

4.  Cheng Lai (8 out of 8 patents)

5.  Weimin Wang (7 out of 7 patents)

6.  Utsav Saxena (7 out of 7 patents)

7.  Natalie Wayne Pursell (6 out of 7 patents)

8.  Martin Koser (5 out of 5 patents)

9.  Naim Nazef (5 out of 5 patents)

10.  Shanthi Ganesh (5 out of 6 patents)

11.  Jihye Park (4 out of 5 patents)

12.  Wen Han (4 out of 4 patents)

13.  Anton Turanov (4 out of 4 patents)

14.  Sujit Basu (3 out of 5 patents)

15.  Qingyi Li (2 out of 9 patents)


Core Competencies:
Gene Expression
Hepatitis B
Double-Stranded RNA
Alpha-1 Antitrypsin
Glycolate Oxidase
Lactate Dehydrogenase
CRISPR Technology
Oligonucleotides
Immunotherapy
Nucleic Acid
Antithrombin 3
PCSK9

102 patents:

1. 12735710 - COMPOSITIONS AND METHODS FOR INHIBITING ANGPTL3 EXPRESSION (2026-09-15),
2. 12674169 - Compositions and methods for modulatingactivity (2026-07-07),
3. 12564601 - METHODS FOR TREATING HEPATITIS B INFECTION (2026-03-03),
4. 12435336 - Compositions and methods for inhibiting LPA expression (2025-10-07),
5. 12252691 - Compositions and methods for inhibiting LPA expression (2025-03-18),
6. 12234456 - Compositions and methods for modulating APOC3 expression (2025-02-25),
7. 12084662 - Compositions and methods for modulating PNPLA3 expression (2024-09-10),
8. 12077756 - Extended dicer substrate agents and methods for the specific inhibition of gene expression (2024-09-03),
9. 12037586 - 4'-phosphate analogs and oligonucleotides comprising the same (2024-07-16),
10. 12037358 - Compositions comprising reversibly modified oligonucleotides and uses thereof (2024-07-16),
11. 11952574 - Compositions and methods for inhibiting transmembrane serine protease 6 (TMPRSS6) expression (2024-04-09),
12. 11912996 - Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA (2024-02-27),
13. 11873493 - Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA (2024-01-16),
14. 11873488 - Double-stranded nucleic acid inhibitor molecules modified with Tm-increasing nucleotides (2024-01-16),
15. 11851658 - Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA (2023-12-26),
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of RNA interference (RNAi)-based therapeutics. We are committed to leveraging our proprietary GalXC™ RNAi technology platform to develop innovative medicines for patients with rare diseases, liver diseases, cardiovascular diseases, and more.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

Dicerna Pharmaceuticals, Inc.
102 Patents

#8 in Lexington, MA

#201 in Massachusetts

#3,713 in US

#7,633 in the World

Lexington, MA (US)
Lexington, MA, United States of America

Dicerna Pharmaceuticals, Inc.

Forward Citations = 398

37 inventors:

goldMedal Bob Dale Brown (79 out of 96 patents)

silverMedal Henryk T Dudek (57 out of 65 patents)

bronzeMedal Marc Abrams (14 out of 15 patents)

4.  Cheng Lai (8 out of 8 patents)

5.  Weimin Wang (7 out of 7 patents)

Please report any incorrect information to [email protected]
Loading…